β-amyloid protein structure determines the nature of cytokine release from rat microglia

Journal of Molecular Neuroscience

Volumn 27, Issue 1, 2005, Pages 1-12

  Lindberg, Catharina ^a   Selenica, Maj Linda Bardyl ^b   Westlind Danielsson, Anita ^b   Schultzberg, Marianne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b H LUNDBECK A S   (Denmark)

Author keywords

Alzheimer's disease; ELISA; Inflammatory; Interferon ; Interleukin 1; Receptor antagonist

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOMER; OLIGOMER; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; INCUBATOR; INFLAMMATION; MICROGLIA; NEWBORN; NONHUMAN; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RAT; TISSUE CULTURE;

AMYLOID BETA-PROTEIN; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MICROGLIA; PEPTIDE FRAGMENTS; PREGNANCY; PROTEIN CONFORMATION; RATS; RATS, WISTAR;

EID: 23444455475     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:27:01:01     Document Type: Article

References (77)

1. SWE transgenic mice. J. Neuroimmunol. 126, 50-57.
2. Aisen P. S., Schafer K. A., Grundman M., Pfeiffer E., Sano M., Davis K. L., et al. (2003) Alzheimer's disease cooperative study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2819-2826.
3. Aksenova M. V., Aksenov M. Y., Butterfield D. A., and Carney J. M. (1996) α-1-Antichymotrypsin interaction with Aβ (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci. Lett. 211, 45-48.
4. Araujo D. M. and Cotman C. W. (1992) β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res. 569, 141-145.
5. Ard M. D., Cole G. M., Wei J., Mehrle A. P., and Fratkin J. D. (1996) Scavenging of Alzheimer's amyloid β-protein by microglia in culture. J. Neurosci. Res. 43, 190-202.
6. Bard F., Cannon C., Barbour R., et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
7. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., et al. (1991) Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285, 111-114.
8. Benveniste E. N., Nguyen V. T., and O'Keefe G. M. (2001) Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem. Int. 39, 381-391.
9. Bitan G. and Teplow D. B. (2004) Rapid photochemical crosslinking - a new tool for studies of metastable, amyloidogenic protein assemblies. Acc. Chem. Res. 37, 357-364.
10. Blasko I., Ransmayr G., Veerhuis R., Eikelenboom P., and Grubeck-Loebenstein B. (2001) Does IFNγ play a role in neurodegeneration? J. Neuroimmunol. 116, 1-4.
11. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., and Riederer P. (1995) Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20.
12. Cacabelos R., Barquero M., Garcia P., Alvarez X. A., and Varela de Seijas E. (1991) Cerebrospinal fluid interleukin-1 β(IL-1 β) in Alzheimer's disease and neurological disorders. Methods Find. Exp. Clin. Pharmacol. 13, 455-458.
13. Cleary, J. P., Walsh D. M., Hofmeister J. J., et al. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nature Neurosci. 8, 79-84.
14. Combs C. K., Karlo J. C., Kao S. C., and Landreth G. E. (2001) β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179-1188.
15. Dahlgren K. N., Manelli A. M., Stine W. B. Jr., Baker L. K., Krafft G. A., and LaDu M. J. (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046-32053.
16. Del Bo R., Angeretti N., Lucca E., De Simoni M. G., and Forloni G. (1995) Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures. Neurosci. Lett. 188, 70-74.
17. Dickson D. W., Lee S. C., Mattiace L. A., Yen S. H., and Brosnan C. (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7, 75-83.
18. Eikelenboom P., Zhan S. S., van Gool W. A., and Allsop D. (1994) Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15, 447-450.
19. Engelborghs S., De Brabander M., De Cree J., D'Hooge R., Geerts H., Verhaegen H., and De Deyn P. P. (1999) Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem. Int. 34, 523-530.
20. Eriksson C., Van Dam A.-M., Lucassen P. J., Bol J. G. J., Winblad B., and Schultzberg M. (1999) Immunohistochemical localization of interleukin-1β, interleukin-1 receptor antagonist and interleukin-1β converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 93, 915-930.
21. Flavin M. P. and Ho L. T. (1999) Propentofylline protects neurons in culture from death triggered by macrophage or microglial secretory products. J. Neurosci. Res. 56, 54-59.
22. Forloni G., Demicheli F., Giorgi S., Bendotti C. and Angeretti N. (1992) Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Mol. Brain Res. 16, 128-134.
23. Fukumoto H., Asami-Odaka A., Suzuki N., and Iwatsubo T. (1996) Association of Aβ 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Neurodegeneration 5, 13-17.
24. Gitter B. D., Cox L. M., Rydel R. E., and May P. C. (1995) Amyloid β peptide potentiates cytokine secretion by interleukin-1 β-activated human astrocytoma cells. Proc. Natl. Acad. Sci. U. S. A. 92, 10738-10741.
25. Giulian D., Haverkamp L. J., Yu J. H., Karshin W., Tom D., Li J., et al. (1996) Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16, 6021-6037.
26. Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., et al. (2003) Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 100, 10417-10422.
27. Griffin W. S., Sheng J. G., Roberts G. W., and Mrak R. E. (1995) Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54, 276-281.
28. Griffin W. S., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., et al. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 86, 7611-7615.
29. Hampel H., Schoen D., Schwarz M. J., et al. (1997) Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 228, 143-146.
30. Harper J. D., Wong S. S., Lieber C. M., and Lansbury P. T. (1997) Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125.
31. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., et al. (1999) Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884.
32. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., and Sato K. (2003) Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl. Acad. Sci. U. S. A. 100, 6370-6375.
33. Hu J., Akama K. T., Krafft G. A., Chromy B. A., and Van Eldik L. J. (1998) Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785, 195-206.
34. Ingelsson M., Fukumoto H., Newell K. L., Growdon J. H., Hedley-Whyte E. T., Frosch M. P., et al. (2004) Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931.
35. Isobe I., Yanagisawa K., and Michikawa M. (2000) A possible model of senile plaques using synthetic amyloid β-protein and rat glial culture. Exp. Neurol. 162, 51-60.
36. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. (1994) Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 13, 45-53.
37. Jarrett J. T., Berger E. P., and Lansbury P. T. Jr. (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
38. Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., and Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
39. 42 in Alzheimer's disease. Hum. Mol. Genet. 9, 2589-2598.
40. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95, 6448-6453.
41. Lanzrein A. S., Johnston C. M., Perry V. H., Jobst K. A., King E. M., and Smith A. D. (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1β, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α, the soluble tumor necrosis factor receptors I and II, and α1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12, 215-227.
42. Lee Y. B., Nagai A., and Kim S. U. (2002) Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 69, 94-103.
43. Levine H. III. (1995) Soluble multimeric Alzheimer β(1-40) pre-amyloid complexes in dilute solution. Neurobiol. Aging 16, 755-764.
44. 1-40 peptide stimulates interleukin-1β release from rat microglia more potently than aggregated forms, in The 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden.
45. Lindberg C., Westlind-Danielsson A., and Schultzberg M. (2003) β-Amyloid-stimulated release of pro- and anti-inflammatory cytokines from rat microglia: differential response to soluble and aggregated forms, in The Society for Neuroscience 33rd Annual Meeting, New Orleans, LA.
46. Lorton D., Kocsis J. M., King L., Madden K., and Brunden K. R. (1996) β-Amyloid induces increased release of interleukin-1β from lipopolysaccharide-activated human monocytes. J. Neuroimmunol. 67, 21-29.
47. Mann D. M., Iwatsubo T., Fukumoto H., Ihara Y., Odaka A., and Suzuki N. (1995) Microglial cells and amyloid β protein (Aβ) deposition; association with A β 40-containing plaques. Acta Neuropathol. 90, 472-477.
48. Martinez M., Fernandez-Vivancos E., Frank A., De la Fuente M., and Hernanz A. (2000) Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res. 869, 216-219.
49. Mattson M. P., Cheng B., Culwell A. R., Esch F. S., Lieberburg I., and Rydel R. E. (1993) Evidence for excito-protective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein. Neuron 10, 243-254.
50. McGeer E. G. and McGeer P. L. (2003) Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 741-749.
51. McGeer P. L., McGeer E., Rogers J., and Sibley J. (1990) Anti-inflammatory drugs and Alzheimer disease. Lancet 335, 1037.
52. Meda L., Cassatella M. A., Szendrei G. I., Otvos L. Jr., Baron P., Villalba M., et al. (1995) Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374, 647-650.
53. Murphy G. M. Jr., Yang L., and Cordell B. (1998) Macrophage colony-stimulating factor augments γ-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J. Biol. Chem. 273, 20967-20971.
54. Näslund J., Haroutunian V., Mohs R., Davis K. L., Davies P., Greengard P., and Buxbaum J. D. (2000) Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
55. Neuroinflammation Working Group, Akiyama H., Barger S., et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
56. Palmblad M., Westlind-Danielsson A., and Bergquist J. (2002) Oxidation of methionine 35 attenuates formation of amyloid β-peptide 1-40 oligomers. J. Biol. Chem. 277, 19506-19510.
57. Päiviö A., Jarvet J., Gräslund A., Lannfelt L., and Westlind-Danielsson A. (2004) Unique physicochemical profile of β-amyloid peptide variant Aβ1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. J. Mol. Biol. 339, 145-159.
58. Roher A. E., Lowenson J. D., Clarke S., Woods A. S., Cotter R. J., Gowing E., and Ball M. J. (1993) β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90, 10836-10840.
59. Scheuner D., Eckman C., Jensen M., et al. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870.
60. Schultzberg M., Tingsborg S., Nobel S., Lundkvist J., Svenson S., Simoncsits A., and Bartfai T. (1995) Interleukin-1 receptor antagonist protein and mRNA in the rat adrenal gland. J. Interferon Cytokine Res. 15, 721-729.
61. Selkoe D. J. (1994) Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10, 373-403.
62. Selkoe D. J. (2002) Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110, 1375-1381.
63. Singh V. K. and Guthikonda P. (1997) Circulating cytokines in Alzheimer's disease. J. Psychiatr. Res. 31, 657-660.
64. Smits H. A., van Beelen A. J., de Vos N. M., Rijsmus A., van der Bruggen T., Verhoef J., et al. (2001) Activation of human macrophages by amyloid-β is attenuated by astrocytes. J. Immunol. 166, 6869-6876.
65. Solerte S. B., Cravello L., Ferrari E., and Fioravanti M. (2000) Overproduction of IFN-γ and TNF-α from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci. 917, 331-340.
66. Szczepanik A. M., Rampe D., and Ringheim G. E. (2001) Amyloid-β peptide fragments p3 and p4 induce proinflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. 77, 304-317.
67. Szekely C. A., Thorne J. E., Zandi P. P., Ek M., Messias E., Breitner J. C., and Goodman S. N. (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159-169.
68. 2- sensitive microglial activation. J. Pharmacol. Sci. 91, 330-333.
69. Tarkowski E., Blennow K., Wallin A., and Tarkowski A. (1999) Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J. Clin. Immunol. 19, 223-230.
70. Tarkowski E., Liljeroth A. M., Nilsson A., Minthon L., and Blennow K. (2001) Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12, 314-317.
71. Vandenabeele P. and Fiers W. (1991) Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol. Today 12, 217-219.
72. Vehmas A. K., Kawas C. H., Stewart W. F., and Troncoso J. C. (2003) Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol. Aging 24, 321-331.
73. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., and Schenk D. B. (1993) Characterization of β-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 1965-1968.
74. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., and Teplow D. B. (1997) Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372.
75. Walsh D. M., Kylubin I., Cleary J. P., et al. (2004) Natural, cell-derived Aβ oligomers: their production, biological activity and inhibition. Neurobiol. Aging 25, 161.
76. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., et al. (2002) Soluble oligomers of β- amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140.
77. Westlind-Danielsson A. and Arnerup G. (2001) Spontaneous in vitro formation of supramolecular β-amyloid structures, "βamy ballsβ, by β-amyloid 1-40 peptide. Biochemistry 40, 14736-14743.